Paclitaxel Albumin-Bound — Drug Intelligence | 81 EU Trials

Filter these 81 trials by condition, phase, country and more.

Open in Search →

81 Registered trials

35 Recruiting

40 Completed trials

49 Sponsors

21 Countries

Phase III

Phase II

Phase III: 38 Phase II/III: 6 Phase II: 23 Phase I/II: 6 Phase IV: 2 Phase I (FiH): 6

Oversight events:

1 serious breach 10 temporary halts 3 urgent safety measures 2 unexpected events 1 corrective measure across 10 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 7 Triple negative breast cancer 4 Breast cancer 4 Hormone receptor positive breast cancer 3 Breast cancer metastatic 3 Peritoneal neoplasm 2 Fallopian tube cancer 2 Hormone receptor positive HER2 negative breast cancer 2 Non-small cell lung cancer 2 Ovarian cancer 2 Haematological malignancy 1 Invasive breast carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 12 F. Hoffmann-La Roche AG 5 Gilead Sciences Inc. 5 AstraZeneca AB 4 Bristol-Myers Squibb Services Unlimited Company 4 Genmab A/S 3 Unicancer 3 Corcept Therapeutics Inc. 2 IRCCS Istituto Nazionale Tumori Fondazione Pascale 2 Region Hovedstaden 2 Aalborg University Hospital 1 Actuate Therapeutics Limited 1

All trials — page 2

81 total

An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therap… Recruiting

2024-512520-11-00 Phase I/II 1 country NEC Bio Therapeutics GmbH
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc… Recruiting

2023-509465-20-00 Phase III 1 country Amsterdam UMC
HARMONi-3 Recruiting

2024-513087-26-00 Phase III 9 countries Summit Therapeutics Inc.
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Phase III 10 countries Merck Sharp & Dohme LLC
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting

2023-505298-34-00 Phase II 1 country Unicancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate… Recruiting

2023-503295-25-00 Phase II/III 1 country Fondazione GONO G.I.
A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic c… Recruiting

2024-514291-41-00 Phase II 1 country Aalborg University Hospital
Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P… Recruiting

2024-518710-11-00 Phase II 2 countries IRCCS Istituto Nazionale Tumori Fondazione Pascale
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non… Recruiting

2024-518937-26-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting

2022-501181-22-01 Phase II 1 country Hopital Erasme
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country Institut Jules Bordet
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cance… Recruiting

2024-515344-23-00 Phase II 1 country Institut Regional Du Cancer De Montpellier
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Phase III 1 country Unicancer
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting

2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Phase II/III 15 countries Bristol-Myers Squibb Services Unlimited Company
A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended

2024-515772-12-00 Phase II 5 countries Merck Sharp & Dohme LLC
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended

2024-516063-89-00 Phase III 4 countries Revolution Medicines Inc.
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended

2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
The role of sonoporation-enhanced treatment in patients with inoperable pancreatic cancer Ended

2024-512176-35-00 Phase II 1 country Helse Bergen HF
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 Phase III 7 countries Dualitybio Inc.
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended

2022-501561-51-00 Phase II 1 country Institut Curie

Showing 25–48 of 81 trials

← All drugs A–Z